OncoMatch/Bladder Cancer (Urothelial)/FGFR3
Bladder Cancer (Urothelial)FGFR3 Clinical Trials
FGFR3 mutations and fusions occur in approximately 15–20% of advanced urothelial carcinoma and are more prevalent in low-grade and upper tract tumors. Erdafitinib is FDA-approved for FGFR3/FGFR2-altered advanced urothelial carcinoma after prior platinum; a front-line approval in the FGFR3-altered setting is also under regulatory review. Trials investigate erdafitinib combinations with enfortumab vedotin and pembrolizumab, next-generation FGFR inhibitors, and FGFR3-directed ADCs.
Top recruiting FGFR3 Bladder Cancer (Urothelial) trials
Ranked by phase and US site count. See all 5 trials matched to your profile →
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Yuanquan Yang
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
Spanish Oncology Genito-Urinary Group
A Phase 2 Clinical Study of ABSK061 and ABSK043
Abbisko Therapeutics Co, Ltd
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company
Browse other molecular targets with active Bladder Cancer (Urothelial) trials.